Endocrinology

The genomes associated with a higher risk of CHD are also associated with higher T2D risk, revealing the possibility of a treatment for both.

Sanofi’s dual SGLT1 and SGLT2 inhibitor was statistically significantly superior to placebo in patients with type 1 diabetes (T1D) on background insulin therapy.

A substance known as epicatechin monomers helps the body release more insulin and respond more efficiently to increased blood glucose, which could in turn benefit type 2 diabetics.

Patients in the combination arm also reached the target HbA1c level faster than those using just the single treatment therapy.

Previous guidelines indicated bypass surgery is preferable for diabetics generally, but new research sought to find out if the same held true for the relatively small number of type 1 diabetics.

Women with type 1 diabetes carry a higher risk of AFib than both men and the general public as a whole.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.

Merck's drug showed a 9% reduction in risk of major cardiovascular events in the REVEAL trial.

In just 9 days of limited fructose consumption, both liver fat concentration and de novo lipogensis decreased.

What's new in research on bisphosphonates, body-fat measurement, prebiotics, and insulin dosing? Find out with our quiz.

CGM has shown to be beneficial to T2D patients who utilize it, although barriers may prevent widespread use.

Researchers say they now understand the mechanism by which inflammatory processes in the liver cause an increase in cholesterol and thus heart disease.

The study highlighted the need to intensify treatment for glycemic control sooner than current methods suggest.

Glucommander is now approved for various enhancements in its patient service capabilities.

Sulforaphane has been found to lower glucose production and improve control in T2D patients.

A new study suggests type 2 diabetes progresses, or perhaps begins, in a manner similar to prion diseases like mad cow disease.

The drug will receive a ruling on Aug. 25. It's currently approved to treat type 2 diabetes and obesity.

A recent study suggests that weight change should be considered in GDM screening for pregnant mothers.

A meta-analysis of 9 studies found that water-based exercise is an equal alternative for type 2 diabetics.

Patients with diabetes, hypertension, and who smoked were found to be more likely to develop dementia, regardless of race.

A biomarker for pancreatic precursor cells might give researchers a shortcut to create insulin-producing beta cells that can be transplanted into patients with type 1 diabetes.

The injunction stands until the company complies with FD&C Act regulations.

Comparison of 6 HARMONY trials showed that albiglutide not only treats type 2 diabetes as effectively as current methods but may reduce the burden felt by other injection-based treatments.

Higher levels of nighttime noise exposure during the first trimester showed correlation with a risk for GDM.

Consuming alcohol 3-4 times per week was associated with a 27% decrease in men's risk, and 32% decrease in women's.

Despite the results of a large-scale trial, some experts questioned the use of beta-blockers for patients that suffered from heart failure and simultaneous AFib when in the presence of beta-adverse medications, like amiodarone.

A study from the University of Warwick revealed a link between levels of gut hormone FGF-19 and diabetic remission in bariatric surgical patients.

A secondary study revealed that the presence of diabetes mellitus in patients with chronic heart failure leads to a higher risk of early death.

Diabetics suffering from severe NPDR and PDR are significantly more likely to develop visual-function problems than those without diabetic retinopathy.

Trials hold enormous potential, but could take a decade or more to complete.